FDA is looking at shifting some of its compliance resources into real-time monitoring of clinical trial quality, both in terms of investigator activities and implementation of the trial plan.
The aim is a more proactive approach that finds deficiencies as they emerge, rather than after they occur, according to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?